financetom
Business
financetom
/
Business
/
BMO Comments on Canada's Strong Wages
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
BMO Comments on Canada's Strong Wages
Nov 29, 2024 5:40 AM

08:20 AM EST, 11/29/2024 (MT Newswires) -- The Bank of Canada has been downplaying the persistent strength in some measures of wages, notably the near-5% year-over-year rise in average hourly wages in the LAbour Force Survey (LFS), said Bank of Montreal (BMO).

However, the companion payroll employment survey (SEPH) is, if anything, now sending an even louder message of caution from wages, noted the bank.

The SEPH survey revealed that the fixed-weight measure of average hourly earnings rose 5.2% year over year in September. That's down from 6.0% the prior month, but that reading was the highest in 33 years of data, stated BMO.

By this measure, wages are running far above core inflation, even as productivity has stalled, pointed out the bank. The two small notes of comfort from an inflation perspective are: 1) wages don't really lead to inflation, and 2) a much softer job market should eventually cool these trends.

However, it's notable how sticky wages remain, added BMO.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Soleno Therapeutics posts Q3 profit on strong VYKAT XR sales 
Soleno Therapeutics posts Q3 profit on strong VYKAT XR sales 
Nov 4, 2025
Overview * Soleno Q3 net income at $26 mln, achieving profitability with VYKAT XR sales * VYKAT XR sales reach $66 mln in Q3, more than doubling from previous quarter * Company raised $230 mln through stock offering, strengthening financial position Outlook * Soleno expects selling, general and administrative expenses to rise post-VYKAT XR commercialization Result Drivers * VYKAT XR...
Mirum Pharmaceuticals Q3 revenue rises on LIVMARLI sales growth
Mirum Pharmaceuticals Q3 revenue rises on LIVMARLI sales growth
Nov 4, 2025
Overview * Mirum Pharmaceuticals Q3 2025 revenue rises 47% yr/yr to $133 mln * Net income for Q3 2025 at $2.9 mln, a turnaround from loss last year * Mirum updates 2025 revenue guidance to $500-$510 mln Outlook * Mirum updates 2025 revenue guidance to $500-$510 mln * Company expects VISTAS study topline data in Q2 2026 * Mirum anticipates...
Day One Biopharmaceuticals Q3 revenue beats estimates on OJEMDA strength
Day One Biopharmaceuticals Q3 revenue beats estimates on OJEMDA strength
Nov 4, 2025
Overview * Day One Q3 revenue of $39.8 mln beats analyst expectations * OJEMDA net product revenue rises 15% from Q2, driven by higher patient demand * Company raises full-year 2025 OJEMDA revenue guidance to $145-$150 mln Outlook * Company raises OJEMDA full-year 2025 revenue guidance to $145-$150 mln Result Drivers * INCREASED DEMAND - OJEMDA net product revenue rose...
Tech firm Mercury Systems Q1 profit beats expectations on strong demand 
Tech firm Mercury Systems Q1 profit beats expectations on strong demand 
Nov 4, 2025
Overview * Mercury Systems ( MRCY ) fiscal Q1 rev grows 10.2% yr/yr, beating analyst expectations * Adjusted EPS for fiscal Q1 beats consensus, improving significantly year-over-year * Company announced $200 mln share repurchase program, reflecting confidence in future prospects Outlook * Mercury Systems ( MRCY ) did not provide specific future revenue or EPS guidance in the statement Result...
Copyright 2023-2026 - www.financetom.com All Rights Reserved